MX2020004883A - Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. - Google Patents

Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.

Info

Publication number
MX2020004883A
MX2020004883A MX2020004883A MX2020004883A MX2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A
Authority
MX
Mexico
Prior art keywords
exosomes
methods
payloads
luminal
loading
Prior art date
Application number
MX2020004883A
Other languages
English (en)
Inventor
Kevin P Dooley
Russell E Mcconnell
Ke Xu
Sonya Haupt
John D Kulman
Douglas E Williams
Rane A Harrison
Damian J Houde
Madeleine Youniss
Original Assignee
Codiak Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codiak Biosciences Inc filed Critical Codiak Biosciences Inc
Publication of MX2020004883A publication Critical patent/MX2020004883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)

Abstract

La presente invención se refiere a métodos para preparar un exosoma terapéutico usando proteínas recientemente identificadas para ser enriquecidas en el lumen de exosomas. Específicamente, la presente invención proporciona métodos para localizar una proteína o péptido terapéutico en exosomas. Los métodos implican la generación de exosomas modificados en el lumen que incluyen una o más de las proteínas de exosoma a concentraciones mayores, una modificación o un fragmento de la proteína de exosoma, o una proteína de fusión de la proteína de exosoma y una proteína terapéutica o de carga.
MX2020004883A 2017-11-17 2018-11-16 Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. MX2020004883A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587767P 2017-11-17 2017-11-17
US201862634750P 2018-02-23 2018-02-23
PCT/US2018/061679 WO2019099942A1 (en) 2017-11-17 2018-11-16 Compositions of engineered exosomes and methods of loading luminal exosomes payloads

Publications (1)

Publication Number Publication Date
MX2020004883A true MX2020004883A (es) 2020-08-06

Family

ID=66534134

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004883A MX2020004883A (es) 2017-11-17 2018-11-16 Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.

Country Status (11)

Country Link
US (3) US20190151456A1 (es)
JP (2) JP2021503300A (es)
KR (2) KR20200091390A (es)
CN (2) CN120204412A (es)
AR (1) AR115159A1 (es)
AU (1) AU2018367670A1 (es)
CA (2) CA3082588A1 (es)
IL (1) IL274634A (es)
MX (1) MX2020004883A (es)
SG (1) SG11202003871SA (es)
WO (1) WO2019099942A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3377043A4 (en) 2015-11-20 2019-06-26 The Regents of The University of California DEVICABLE NANOSCAL CARRIER (DNVS) FOR ADMINISTRATION THROUGH THE BLOOD-BRAIN-BARRIER, MICE AND SKIN
CN110662532A (zh) 2017-04-03 2020-01-07 加利福尼亚大学董事会 用于跨血脑屏障、透粘膜和经皮药物递送的可变形的纳米级媒介物(dnvs)
PL3684381T3 (pl) * 2017-09-21 2023-03-13 Codiak Biosciences, Inc. Wytwarzanie pęcherzyków zewnątrzkomórkowych w zawiesinie pojedynczych komórek z zastosowaniem zdefiniowanych chemicznie pożywek do hodowli komórkowych
US20220017907A1 (en) * 2017-11-17 2022-01-20 Codiak Biosciences, Inc. Engineered extracellular vesicles and uses thereof
US12066382B2 (en) 2018-06-21 2024-08-20 Lonza Sales Ag Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering
EP4059510B1 (en) * 2018-11-16 2025-05-21 Lonza Sales AG Engineered extracellular vesicles and uses thereof
JP2022519275A (ja) 2019-02-04 2022-03-22 コディアック バイオサイエンシーズ， インコーポレイテッド エクソソーム操作のための膜タンパク質足場
WO2020191361A2 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
WO2020215010A1 (en) * 2019-04-17 2020-10-22 Codiak Biosciences, Inc. Compositions of exosomes and aav
WO2020231700A1 (en) * 2019-05-11 2020-11-19 Youngsuk Yi Neurotoxin compositions and methods
US20220251200A1 (en) 2019-07-03 2022-08-11 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
CN114729327A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 具有stat3反义寡核苷酸的细胞外囊泡
CN120771302A (zh) * 2019-08-14 2025-10-14 隆萨销售股份公司 与分子连接的细胞外囊泡及其用途
CN114729356A (zh) * 2019-08-14 2022-07-08 科迪亚克生物科学公司 靶向stat6的细胞外囊泡-aso构建体
EP4013872A1 (en) * 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicles with antisense oligonucleotides targeting kras
EP4013878A1 (en) 2019-08-14 2022-06-22 Codiak BioSciences, Inc. Extracellular vesicle-aso constructs targeting cebp/beta
CA3147365A1 (en) * 2019-08-14 2021-02-18 Joanne LIM Extracellular vesicle-nlrp3 antagonist
CN114727947A (zh) 2019-09-25 2022-07-08 科迪亚克生物科学公司 细胞外囊泡组合物
US20230103726A1 (en) 2019-09-25 2023-04-06 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
WO2021062057A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Exogenous loading of exosomes via lyophilization
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
JP2022551420A (ja) 2019-09-25 2022-12-09 コディアック バイオサイエンシーズ， インコーポレイテッド 腫瘍を治療するためのｉｌ－１２提示エクソソームとｓｔｉｎｇアゴニスト含有エクソソームとの併用
WO2021092193A1 (en) 2019-11-05 2021-05-14 Codiak Biosciences, Inc. High-throughput chromatography screening for extracellular vesicles
EP4090974A1 (en) 2020-01-17 2022-11-23 Codiak BioSciences, Inc. Cholesterol assays for quantifying extracellular vesicles
JP7562682B2 (ja) * 2020-01-27 2024-10-07 マントラ バイオ，インコーポレイテッド キメラ小胞局在化部分を含む非天然発生の小胞、その産生方法、およびその使用
KR20220139926A (ko) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 인공 시냅스
CN115667528B (zh) * 2020-03-04 2024-10-01 苏州齐禾生科生物科技有限公司 多重基因组编辑方法和系统
WO2021184020A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Methods of treating neuroinflammation
WO2021184021A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting pmp22
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
AU2021270347A1 (en) 2020-05-11 2022-12-15 Erytech Pharma Red cell extracellular vesicles (RCEVs) containing cargoes and methods of use and production thereof
US20230220068A1 (en) 2020-06-05 2023-07-13 Codiak Biosciences, Inc. Anti-transferrin extracellular vesicles
CN116209430A (zh) * 2020-08-07 2023-06-02 阿米库斯治疗学公司 囊泡靶向蛋白及其用途
JP2023538077A (ja) 2020-08-17 2023-09-06 コディアック バイオサイエンシーズ， インコーポレイテッド がんの治療方法
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
US20230366794A1 (en) 2020-09-23 2023-11-16 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022076596A1 (en) 2020-10-06 2022-04-14 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
CN112410304A (zh) * 2020-11-12 2021-02-26 天津大学 一种基因修饰的外泌体及其制备方法和应用
CN112903999A (zh) * 2021-01-20 2021-06-04 蚌埠医学院第一附属医院（蚌埠医学院附属肿瘤医院） 一种用于纳米流式细胞仪检测的外泌体的制备方法及应用
JP2024512236A (ja) 2021-02-17 2024-03-19 ロンザ セールス アーゲー 細胞外ベシクル－ｎｌｒｐ３アンタゴニスト
CA3207950A1 (en) 2021-02-17 2022-08-25 Kimberly ELLIS Methods of loading extracellular vesicles
CA3213989A1 (en) 2021-04-01 2022-10-06 Conlin O'NEIL Extracellular vesicle compositions
CN115505599A (zh) * 2021-06-23 2022-12-23 艾威亚(广州)医药科技有限公司 Gpi诱导的胰岛素靶向型外泌体的制备及其在递送重组生物药物中的应用
WO2023027082A1 (ja) * 2021-08-23 2023-03-02 積水化学工業株式会社 ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法
CN118119702A (zh) 2021-10-14 2024-05-31 隆萨销售股份有限公司 用于细胞外囊泡产生的经修饰的生产者细胞
WO2023085821A1 (ko) * 2021-11-10 2023-05-19 주식회사 씨케이엑소젠 엑소좀 기반 항바이러스 백신 및 이의 제조방법
WO2023091905A1 (en) * 2021-11-19 2023-05-25 Elmaleh David R Targeted extracellular vesicles and methods of use thereof
CA3246177A1 (en) * 2022-03-24 2023-09-28 Mercury Bio, Inc. DIRECT PRODUCTION OF RNASI IN SACCHAROMYCES BOULARDII AND PACKAGING IN EXTRACELLULAR VESICLES (VE) FOR TARGETED GENE SILENCER
CN117126886A (zh) * 2022-05-20 2023-11-28 谛邈生物科技(北京)有限公司 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用
CN115073611B (zh) * 2022-06-21 2025-10-21 中国人民解放军空军军医大学 一种便于选择性捕获功能外泌体及其纯化方法和应用
CN116656705A (zh) * 2023-04-18 2023-08-29 河南中医药大学第一附属医院 pHLIP-Lamp2b-1/2融合蛋白重组质粒及其构建、应用
JPWO2025100522A1 (es) * 2023-11-10 2025-05-15
CN121270721B (zh) * 2025-10-22 2026-04-10 广东隆升生物科技研究有限公司 一种干细胞外泌体的制备方法及其在制备药品或化妆品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1412498A2 (en) * 2001-07-17 2004-04-28 Novartis AG Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
PT2419144T (pt) * 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composição para a administração de material genético
WO2012002759A2 (ko) * 2010-07-01 2012-01-05 포항공과대학교 산학협력단 세포의 원형질체에서 유래한 마이크로베시클 및 이의 용도
GB201121069D0 (en) * 2011-12-07 2012-01-18 Isis Innovation Delivery system
WO2016172598A1 (en) * 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
WO2017117585A1 (en) * 2015-12-30 2017-07-06 The Regents Of The University Of California Methods for enhanced production and isolation of cell-derived vesicles
WO2017147719A1 (en) * 2016-03-04 2017-09-08 Exerkine Corporation Method for treating neuropathy

Also Published As

Publication number Publication date
AR115159A1 (es) 2020-12-02
SG11202003871SA (en) 2020-05-28
KR20200091390A (ko) 2020-07-30
JP2024015074A (ja) 2024-02-01
CN111511384A (zh) 2020-08-07
US20190151456A1 (en) 2019-05-23
CA3082588A1 (en) 2019-05-23
US20200347112A1 (en) 2020-11-05
WO2019099942A1 (en) 2019-05-23
AU2018367670A1 (en) 2020-05-07
JP2021503300A (ja) 2021-02-12
CN120204412A (zh) 2025-06-27
IL274634A (en) 2020-06-30
CA3234784A1 (en) 2019-05-23
US20240000944A1 (en) 2024-01-04
CN111511384B (zh) 2025-03-04
KR20250005239A (ko) 2025-01-09

Similar Documents

Publication Publication Date Title
CL2021001278A1 (es) Vesículas extracelulares modificadas y sus usos
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
CO2020001872A2 (es) Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CY1123963T1 (el) Καινοτομα πολυμερικα προφαρμακα hgh
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2018011491A (es) Disposiciones de secuencia y secuencias para presentacion de neoepitopos.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX2016009428A (es) Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
CL2017000311A1 (es) Anticuerpos anti-lag3 y fragmentos de unión a antígeno
MX2018010415A (es) Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
BR112017016019A2 (pt) método para tratamento de câncer, artigo para fabricação, e, kit.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
BR112016027773A2 (pt) peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b